<DOC>
	<DOCNO>NCT01906541</DOCNO>
	<brief_summary>X-linked chronic granulomatous disease ( X-CGD ) rare inherit immune defect , cause inability phagocytic cell produce reactive oxygen specie due defect gp91phox subunit NADPH oxidase complex . X-CGD patient suffer recurrent life-threatening infection severe hyperinflammatory complication . The curative treatment X-CGD allogenic hematopoietic stem cell transplantation , procedure implies severe risk many patient lack appropriate donor . Therefore alternative curative approach urgently need . In study , patient treat gene-corrected autologous CD34+ cell , use SIN gammaretroviral vector ex-vivo gene-therapy .</brief_summary>
	<brief_title>Gene Therapy X-CGD</brief_title>
	<detailed_description />
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<criteria>Verified diagnosis Xlinked form chronic granulomatous disease , loss gp91phox expression ( Western Blot ) . Evidence less 5 % normal oxidase production circulate neutrophil granulocyte measure dihydrorhodamine ( DHR ) nitro blue tetrazolium ( NBT ) assay History severe chronic infection lifethreatening course severe steroid sensitive steroid insensitive granulomatous disease , necessity inpatient treatment , without sustain improvement even maximum conservative treatment measure No Human Leukocyte Antigen ( HLA ) identical ( 10/10 match ) sibling unrelated donor , contraindication allogenic stem cell transplantation presence suitable donor . The lack HLAidentical ( 10/10 match ) sibling unrelated donor confirm unsuccessful search national international donor register leat 3 month Normal organfunction : glomerular filtration rate ( GFR ) ≥ 60ml/min. , Bilirubin ≤ 1.5fold upper referencelevel , normal parameter liver enzymes clot ( TPZ 75100 % , partial thromboplastin time ( PTT ) 3038sec , Fibrinogen 200400mg/dl ) , Leukocytes &gt; 3 x 10^9/l , Granulocytes &gt; 1.5 x 10^9/l , Thrombocytes &gt; 100 x 10^9/l Contraception start GCSF application 1 year retransfusion genecorrected cell No interferongamma injection within two week prior hematopoietic stem cell mobilization KarnofskyIndex &gt; 70 % Signed informed consent Patients noncontrolled acute infection Severe cardiac pulmonary malfunction : ejection fraction &lt; 60 % , valvular heart disease &gt; II° , arrhythmia require therapy , force expiratory volume one second/vital capacity ( FEV1/VC ) &lt; 75 % , diffusion capacity lung carbon monoxide ( DLCO ) &lt; 60 % Bilirubin &gt; 1.5fold upper referencelevel HIV , Hepatitis B C infection Contraindications GCSF administration , autoimmune vasculitis . Contraindications stem cell apheresis , low hemoglobin &lt; 8g/dl , cardiovascular instability severe coagulopathy Pregnancy breastfeed Drug alcoholabuse Lack search unrelated donor Patients HLA 9/10 mismatch unrelated donor ( MMUD ) exclude , thorough riskbenefit analysis favor allogenic hematopoietic stem cell transplantation ( HSCT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>X-CGD</keyword>
	<keyword>chronic granulomatous disease</keyword>
	<keyword>gene-therapy</keyword>
</DOC>